Switch theme
Sign up to access all valuation multiples
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
2011
26
LTM Revenue n/a
LTM EBITDA -$55.0M
$469M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Trevi Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$55.0M.
In the most recent fiscal year, Trevi Therapeutics achieved revenue of n/a and an EBITDA of -$47.8M.
Trevi Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Trevi Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$28.6M | -$47.8M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$29.2M | -$29.1M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Trevi Therapeutics's stock price is $6.
Trevi Therapeutics has current market cap of $575M, and EV of $469M.
See Trevi Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $469M | $575M | XXX | XXX | XXX | XXX | $-0.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Trevi Therapeutics has market cap of $575M and EV of $469M.
Trevi Therapeutics's trades at n/a LTM EV/Revenue multiple, and -8.5x LTM EBITDA.
Analysts estimate Trevi Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Trevi Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $469M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -9.8x | XXX | XXX | XXX |
| P/E | -12.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -12.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTrevi Therapeutics's NTM/LTM revenue growth is n/a
Trevi Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.0M for the same period.
Over next 12 months, Trevi Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Trevi Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Trevi Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 67% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Trevi Therapeutics acquired XXX companies to date.
Last acquisition by Trevi Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Trevi Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Trevi Therapeutics founded? | Trevi Therapeutics was founded in 2011. |
| Where is Trevi Therapeutics headquartered? | Trevi Therapeutics is headquartered in United States of America. |
| How many employees does Trevi Therapeutics have? | As of today, Trevi Therapeutics has 26 employees. |
| Who is the CEO of Trevi Therapeutics? | Trevi Therapeutics's CEO is Ms. Jennifer L. Good. |
| Is Trevi Therapeutics publicy listed? | Yes, Trevi Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Trevi Therapeutics? | Trevi Therapeutics trades under TRVI ticker. |
| When did Trevi Therapeutics go public? | Trevi Therapeutics went public in 2019. |
| Who are competitors of Trevi Therapeutics? | Similar companies to Trevi Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Trevi Therapeutics? | Trevi Therapeutics's current market cap is $575M |
| What is the current EBITDA of Trevi Therapeutics? | Trevi Therapeutics's last 12-month EBITDA is -$55.0M. |
| What is the current EV/EBITDA multiple of Trevi Therapeutics? | Current EBITDA multiple of Trevi Therapeutics is -8.5x. |
| Is Trevi Therapeutics profitable? | Yes, Trevi Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
